Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Medicinal Mushroom Supplement AHCC Helps Clear “Invisible” HPV Infections

By: NewsUSA

(NewsUSA) - You may be among the 42 million Americans currently infected by the human papillomavirus (HPV) and not know it. HPV is the most common sexually transmitted infection in the United States, affecting more than 70 percent of sexually active adults at least once in their lifetimes. Unlike the “low-risk” HPV strains that produce visible lesions, “high-risk” HPV is an “invisible” infection that can lie undetected for decades and can lead to six different types of cancer; the two most common being cervical and head-and-neck cancers.       

A recent breakthrough in the study of HPV is providing physicians and patients with a new avenue for addressing high-risk infection.  Researchers at the McGovern Medical School at UTHealth Houston studied the effect of a unique natural Japanese medicinal mushroom extract called AHCC® on women with persistent high-risk HPV infections.  They found that daily use of AHCC® helped to clear an active HPV infection in two-thirds of study participants after only six months, while volunteers in the placebo group did not see comparable results.     

The randomized double-blind placebo-controlled trial, considered to be the gold standard protocol for clinical research, was co-funded by the National Institutes of Health (NIH) and published in the June 2022 issue of the prestigious medical journal Frontiers in Oncology.     

Current standard of care entails screening women for HPV during their regular gynecological exam. HPV usually goes undetected in men unless and until they are diagnosed with an HPV-associated cancer; as a result, they often spread the infection without knowing it. When a patient tests positive for HPV, the current protocol is often referred to as “watchful waiting” which entails monitoring the patient’s condition through regular exams but not providing any pharmacological or surgical treatment.     

This latest study shows that there is something that patients can do during this “waiting” period other than just passively anticipating their next exam. “Our results showed that AHCC® supplementation helped the majority of patients in the AHCC® arm of the trial to become HPV-negative, therefore decreasing the long-term risk of HPV-related cancers,” says Dr. Smith. “Importantly, through multiple studies, we have shown that AHCC supplements are safe.”     

There are more than 30 human clinical studies and over 50 papers on AHCC® that have been published in Medline-indexed NIH-recognized scientific journals. AHCC® contains a unique combination of potent active components including alpha-glucans and axoglucan™ fractions, discovered by the Amino Up company of Sapporo, Japan. Numerous reputable supplement brands offer AHCC® in North America. Verified authentic products sold under the registered AHCC® trademark of Amino Up are listed on the AHCC Association website at www.AHCC.net.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.